Cargando…

Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study

INTRODUCTION: To assess the comparative effectiveness and safety of renal-related outcomes associated with sodium-glucose cotransporter-2 inhibitors (SGLT2-i) initiation among patients with type 2 diabetes using real-world data. RESEARCH DESIGN AND METHODS: We conducted a population‐based cohort stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alkabbani, Wajd, Zongo, Arsene, Minhas-Sandhu, Jasjeet K, Eurich, Dean T, Shah, Baiju R, Alsabbagh, Mhd Wasem, Gamble, John-Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Epidemiology/Health services research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671915/ https://www.ncbi.nlm.nih.gov/pubmed/34906925 http://dx.doi.org/10.1136/bmjdrc-2021-002496

Ejemplares similares

Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus
por: Alkabbani, Wajd, et al.
Publicado: (2022)

The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews
por: Pelletier, Ryan, et al.
Publicado: (2020)

Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
por: Yang, Jeff Yufeng, et al.
Publicado: (2020)

Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews
por: Pelletier, Ryan, et al.
Publicado: (2021)

Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
por: Kahkoska, Anna R., et al.
Publicado: (2021)

Does the association between adherence to statin medications and mortality depend on measurement approach? A retrospective cohort study
por: Alsabbagh, Mhd. Wasem, et al.
Publicado: (2017)

The Darkening Cloud of Diabetes: Do trends in cardiovascular risk management provide a silver lining?
por: Eurich, Dean T., et al.
Publicado: (2008)

Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
por: Pintat, Stéphane, et al.
Publicado: (2019)

Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study
por: Sütő, Gábor, et al.
Publicado: (2021)

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
por: Alkabbani, Wajd, et al.
Publicado: (2021)

Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up
por: Eurich, Dean T, et al.
Publicado: (2017)

Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias – A narrative review
por: Huang, Yichang, et al.
Publicado: (2020)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Pharmacists’ chronic disease management in chronic obstructive pulmonary disease: Effect on health services utilization
por: Makhinova, Tatiana, et al.
Publicado: (2023)

The association between the rate of potentially pharmacist-manageable emergency department visits and community income level and primary care provider availability: A spatial analysis
por: Wasem Alsabbagh, Mhd, et al.
Publicado: (2022)

Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport
por: Ferrannini, Ele, et al.
Publicado: (2020)

Effectiveness of RADAR: An Innovative Model to Organize Diabetes Care in First Nations Communities
por: Eurich, Dean T., et al.
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria
por: Delanaye, Pierre, et al.
Publicado: (2021)

Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
por: Castoldi, Giovanna, et al.
Publicado: (2021)

Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
por: Kim, Nam Hoon, et al.
Publicado: (2022)

Cohort study of medical cannabis authorization and motor vehicle crash-related healthcare visits in 2014–2017 in Ontario, Canada
por: Lee, Cerina, et al.
Publicado: (2021)

Optimal threshold of adherence to lipid lowering drugs in predicting acute coronary syndrome, stroke, or mortality: A cohort study
por: Zongo, Arsène, et al.
Publicado: (2019)

Change in Trajectories of Adherence to Lipid‐Lowering Drugs Following Non‐Fatal Acute Coronary Syndrome or Stroke
por: Zongo, Arsène, et al.
Publicado: (2019)

Effect of a pharmacy comprehensive chronic diseases care plan on use of lipid-lowering drugs among patients with hypertension
por: Zongo, Arsène, et al.
Publicado: (2021)

Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol
por: Butterly, Elaine, et al.
Publicado: (2022)

Renal threshold for glucose reabsorption predicts diabetes improvement by sodium‐glucose cotransporter 2 inhibitor therapy
por: Osaki, Aya, et al.
Publicado: (2016)

Effects of Sodium Glucose Cotransporter 2 Inhibitor on Renal Renin-Angiotensin-Aldsoterone System
por: Takeda, Yoshiyu, et al.
Publicado: (2021)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
por: Nunoi, Kiyohide, et al.
Publicado: (2019)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
por: Sano, Ryuhei, et al.
Publicado: (2020)

Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
por: Shao, Shih-Chieh, et al.
Publicado: (2019)

Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation
por: Sano, Motoaki
Publicado: (2020)

Polypharmacy influences the renal composite outcome in patients treated with sodium‐glucose cotransporter 2 inhibitors
por: Kobayashi, Kazuo, et al.
Publicado: (2022)

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Safe opioid prescribing: a prognostic machine learning approach to predicting 30-day risk after an opioid dispensation in Alberta, Canada
por: Sharma, Vishal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1ichg5jfhfelvbbij77jko6ras